IMA NASDAQ
ImageneBio Inc
1W: -2.5%
1M: -7.3%
3M: -23.3%
YTD: -31.9%
1Y: -46.0%
3Y: -91.3%
5Y: -97.0%
$4.60
+0.02 (+0.43%)
Weekly Expected Move ±3.9%
$4
$4
$5
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$51.9M
52W Range3.94-9.1
Volume7,701
Avg Volume13,359
Beta0.71
Dividend—
Analyst Ratings
Company Info
CEOKristin Yarema
Employees18
SectorHealthcare
IndustryBiotechnology
IPO Date1998-02-27
Websiteinmagenebio.com
12526 High Bluff Drive, Suite 345, San Diego, CA 92130
San Diego, CA 92130
US
San Diego, CA 92130
US
858 345 6265
About ImageneBio Inc
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Latest News
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna
Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna
PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals Accelerate Lumbar Fusion
Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yarema Kristin | A-Award | 254,800 | — | 2026-08-14 |
| Yarema Kristin | A-Award | 137,200 | $5.84 | 2026-08-14 |
| Yarema Kristin | A-Award | 250,000 | $5.84 | 2026-08-14 |
| Grant-Huerta Yanina | A-Award | 65,000 | — | 2026-08-14 |
| Grant-Huerta Yanina | A-Award | 39,000 | — | 2026-08-14 |